{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T17:29:52Z","timestamp":1772040592894,"version":"3.50.1"},"reference-count":32,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Practically the entire global population is infected by herpesviruses that establish lifelong latency and can be reactivated. Alpha-herpesviruses, herpes simplex viruses 1 and 2 (HSV-1\/HSV-2) and varicella zoster virus (VZV), establish latency in sensory neurons and then reactivate to infect epithelial cells in the mucosa or skin, resulting in a vesicular rash. Licensed antivirals inhibit virus replication, but do not affect latency. On reactivation, VZV causes herpes zoster, also known as shingles. The 76-year-old first author of this paper published an autobiography of his own severe herpes zoster ophthalmicus (HZO) infection with orbital edema, which is considered an emergency condition. Acyclovir (ACV) treatment was complemented with an immunostimulatory viral therapy, which resolved most symptoms within a few days. The orally administered live-attenuated infectious bursal disease vaccine virus (IBDV) delivers its double-stranded RNA (dsRNA) cargo to host cells and activates the natural antiviral interferon (IFN) gene defense system from within the host cells. IBDV has already been demonstrated to be safe and effective against five different families of viruses, hepatitis A virus (HAV), hepatitis B and C virus (HBV\/HCV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and varicella zoster virus (VZV). Here we propose a short phase I\/II trial in elderly shingles patients who will be assigned to receive either ACV monotherapy or ACV combined with R903\/78, an attenuated immunostimulatory IBDV strain. The primary endpoints will be safety, but the efficacy of the combination therapy against the ACV monotherapy also will be assessed.<\/jats:p>","DOI":"10.3390\/ph16020226","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T02:21:12Z","timestamp":1675304472000},"page":"226","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Combination Therapy for the Treatment of Shingles with an Immunostimulatory Vaccine Virus and Acyclovir"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9145-9276","authenticated-orcid":false,"given":"Tibor","family":"Bakacs","sequence":"first","affiliation":[{"name":"Department of Probability, Alfred Renyi Institute of Mathematics, The Eotvos Lorand Research Network (ELKH), 1053 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Sandig","sequence":"additional","affiliation":[{"name":"ProBioGen AG, 13086 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0322-3969","authenticated-orcid":false,"given":"Imre","family":"Kovesdi","sequence":"additional","affiliation":[{"name":"Unleash Immuno Oncolytics Inc., St. Louis, MO 63110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1172\/JCI136225","article-title":"Herpesvirus latency","volume":"130","author":"Cohen","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2990.2011.01167.x","article-title":"Review: The neurobiology of varicella zoster virus infection","volume":"37","author":"Gilden","year":"2011","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"25151355221084535","DOI":"10.1177\/25151355221084535","article-title":"Global herpes zoster incidence, burden of disease, and vaccine availability: A narrative review","volume":"10","author":"Pan","year":"2022","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"ref_4","first-page":"2","article-title":"Herpes Zoster Clinical Presentation","volume":"2","author":"Janniger","year":"2021","journal-title":"Medscape J. Med."},{"key":"ref_5","first-page":"e20303","article-title":"Healing of Severe Herpes Zoster Ophthalmicus Within a Few Days: An Autobiographical Case Report","volume":"13","author":"Bakacs","year":"2021","journal-title":"Cureus"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1046851","DOI":"10.3389\/fimmu.2022.1046851","article-title":"Editorial: Fighting fire with fire: Using non-pathogenic viruses to control unrelated infections","volume":"13","author":"Bakacs","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Krishnamurthy, N., Grimshaw, A.A., Axson, S.A., Choe, S.H., and Miller, J.E. (2022). Drug repurposing: A systematic review on root causes, barriers and facilitators. BMC Health Serv. Res., 22.","DOI":"10.1186\/s12913-022-08272-z"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.semcancer.2020.01.008","article-title":"Repurposing drugs in oncology: From candidate selection to clinical adoption","volume":"68","author":"Pantziarka","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"688755","DOI":"10.3389\/fonc.2021.688755","article-title":"Repurposing Infectious Diseases Vaccines Against Cancer","volume":"11","author":"Vandeborne","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.3389\/fimmu.2022.877845","article-title":"Prospects on Repurposing a Live Attenuated Vaccine for the Control of Unrelated Infections","volume":"13","author":"Seo","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"907341","DOI":"10.3389\/fimmu.2022.907341","article-title":"Vaccination With Oral Polio Vaccine Reduces COVID-19 Incidence","volume":"13","author":"Yagovkina","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_12","first-page":"e28467","article-title":"An Orally Administered Nonpathogenic Attenuated Vaccine Virus Can Be Used to Control SARSCoV-2 Infection: A Complementary Plan B to COVID-19 Vaccination","volume":"14","author":"Bakacs","year":"2022","journal-title":"Cureus"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/35099560","article-title":"Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3","volume":"413","author":"Alexopoulou","year":"2001","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nri888","article-title":"Viruses and interferon: A fight for supremacy","volume":"2","author":"Katze","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"ref_15","first-page":"37","article-title":"Live enteroviral vaccines for the emergency nonspecific prevention of mass respiratory diseases during fall-winter epidemics of influenza and acute respiratory diseases","volume":"11\u201312","author":"Chumakov","year":"1992","journal-title":"Zh. Mikrobiol. Epidemiol. Immunobiol."},{"key":"ref_16","first-page":"1","article-title":"Therapeutic exploitation of viral interference","volume":"19","author":"Kovesdi","year":"2019","journal-title":"Infect. Disord. Drug Targets"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Qin, Y., and Zheng, S.J. (2017). Infectious Bursal Disease Virus-Host Interactions: Multifunctional Viral Proteins that Perform Multiple and Differing Jobs. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18010161"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1073\/pnas.0906193106","article-title":"The comparative genomics of viral emergence","volume":"107","author":"Holmes","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/jgm.2830","article-title":"Effective multiple oral administration of reverse genetics engineered infectious bursal disease virus in mice in the presence of neutralizing antibodies","volume":"17","author":"Hornyak","year":"2015","journal-title":"J. Gene Med."},{"key":"ref_20","first-page":"1279","article-title":"Preliminary report of a controlled trial of MTH-68\/B virus vaccine treatment in acute B and C hepatitis: A phase II study","volume":"18","author":"Csatary","year":"1998","journal-title":"Anticancer Res."},{"key":"ref_21","first-page":"629","article-title":"Successful treatment of decompensated chronic viral hepatitis by bursal disease virus vaccine","volume":"19","author":"Csatary","year":"1999","journal-title":"Anticancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.vaccine.2004.08.005","article-title":"Examination of the value of treatment of decompensated viral hepatitis patients by intentionally coinfecting them with an apathogenic IBDV and using the lessons learnt to seriously consider treating patients infected with HIV using the apathogenic hepatitis G virus","volume":"23","author":"Bakacs","year":"2004","journal-title":"Vaccine"},{"key":"ref_23","first-page":"e22750","article-title":"Sequential Combination of a Strong Interferon Inducer Viral Vector With Low Doses of Nivolumab Plus Ipilimumab Could Provide Functional Cure in Chronic Hepatitis B Virus infections: Technical Report Proposing a New Modality","volume":"14","author":"Bakacs","year":"2022","journal-title":"Cureus"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/03079457.2016.1138280","article-title":"Continuous cell lines from the Muscovy duck as potential replacement for primary cells in the production of avian vaccines","volume":"45","author":"Jordan","year":"2016","journal-title":"Avian Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jclinepi.2015.05.004","article-title":"CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement","volume":"76","author":"Vohra","year":"2016","journal-title":"J. Clin. Epidemiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"100336","DOI":"10.1016\/j.ebr.2019.100336","article-title":"Making the switch: From case studies to N-of-1 trials","volume":"12","author":"Margolis","year":"2019","journal-title":"Epilepsy Behav. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijid.2018.04.4324","article-title":"Randomized clinical trial of famciclovir or acyclovir for the treatment of herpes zoster in adults","volume":"72","author":"Pott","year":"2018","journal-title":"Int. J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2020.00001","article-title":"Manipulation of the Innate Immune Response by Varicella Zoster Virus","volume":"11","author":"Gerada","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cell.2014.02.032","article-title":"The virome in mammalian physiology and disease","volume":"157","author":"Virgin","year":"2014","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Majewska, A., and Mlynarczyk-Bonikowska, B. (2022). 40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073431"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13256-017-1351-y","article-title":"How to choose the best journal for your case report","volume":"11","author":"Rison","year":"2017","journal-title":"J. Med. Case Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/14653240510027136","article-title":"History of the clinical use of umbilical cord blood hematopoietic cells","volume":"7","author":"Gluckman","year":"2005","journal-title":"Cytotherapy"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/2\/226\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:21:20Z","timestamp":1760120480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/2\/226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ph16020226"],"URL":"https:\/\/doi.org\/10.3390\/ph16020226","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,1]]}}}